FL-ETT
9.7.2024 20:26:35 CEST | Business Wire | Press release
ETT | iByond™, together with WorldVuer established WorldVuer iByond’s joint venture to develop the world’s first artificial intelligence operating system, WiOS (WorldVuer iByond Operating System). This collaboration is poised to modernize the technology estates of global enterprises, multinationals, sovereigns, and governments, leveraging intelligent interoperability, speed of innovation, AI, and an airtight security platform. “WiOS is poised to be one of the next big players to dominate the world stage alongside Android and iOS,” concluded Mr. Michael Sutton, Chief Media Officer of WorldVuer Inc.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240709427149/en/
Dr. Kenneth Ekow Andam, CEO of WorldVuer Inc. & Christopher Condon, Chairman & CEO of ETT | iByond™ (Photo: Business Wire)
ETT | iByond™, renowned for its cutting-edge Intelligent Interoperability AI platform, offers seamless integration and intelligent solutions tailored to enhance business operations across various industries. With a commitment to driving technological advancement, iByond's platform empowers organizations to harness the power of AI, enabling smarter decision-making, improved efficiency, and significant cost savings for enterprises. The iByond platform will serve individual consumers with WorldVuers’ technology products. WorldVuer brings to this venture their existing ecosystem of customers, consisting of 25 countries and 98 Million households, estimated to bring this partnership USD $6 Billion+ in annual software subscription revenues. Additionally, WorldVuer has a diverse portfolio of seven pioneering technologies, each designed to push the boundaries of innovation. WorldVuer’s products are built with an emphasis on security, incorporating airtight cybersecurity measures to ensure the utmost protection for users.
“We are excited to partner with WorldVuer, a company that shares our vision of innovation and excellence,” said Christopher Condon, Chairman and CEO of ETT | iByond™. “This partnership will enable us to deliver an unparalleled AI operating system with the highest level of speed, security, and data connection helping governments and enterprises worldwide to thrive in an increasingly digital world.”
“Innovating an AI Operating System that is built to transition the current global interconnected cloud devices within our communities and countries into an efficient, corroborative, and dynamic Interoperable platform to power current and futuristic devices makes this initiative an exciting opportunity for both WorldVuer and ETT | iByond™,” commented by Dr. Kenneth Ekow Andam, CEO of WorldVuer Inc.
“As we continue to witness extensive adoption and investment in AI across the enterprise and consumer markets globally, the WorldVuer iByond operating system provides breakthrough innovation and value by integrating hardware, software, and platform technologies and services. speed, security, and scale are now in reach at a level far beyond the data management and AI solutions currently available.” Lanny Cohen, Vice-Chairman & CPO, ETT | iByond™
About WorldVuer iByond
At WorldVuer | iByond, a joint venture that provides cutting-edge intelligent technologies powered by the iByond | WiOS system, focused on Enhanced Security, Seamless Data Integration, Improved Data Governance, and Enhanced Collaboration. WorldVuer iByond provides top-tier data protection, smooth data flow, regulatory compliance, and efficient communication, empowering organizations to boost productivity, creativity, and competitiveness. For more information, visit www.worldvueribyond.com
About ETT | iByond™
ETT | iByond™ is a leading provider of transformative solutions for enterprises, specializing in software, infrastructure, and innovations. iByond empowers businesses to embrace digital transformation and unlock new avenues for growth and success in today’s rapidly evolving business environment connecting humanity through intelligent data. For more information, visit www.ettworld.com
About WorldVuer
Leaders in interactive content development. We build products to bring a lifestyle narrative and communications capabilities into your home and office. Buy WorldVuer products and join our new emerging media empowering solutions that help you build success for you and your family. For more information, visit www.wvistore.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240709427149/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 09:31:00 CEST | Press release
Peyman Kargar appointed Director and Chief Executive Officer of TVS Motor Company, effective January 27, 2027 K. N. Radhakrishnan to continue as Director and Chief Executive Officer until then and subsequently will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027 Appointment supports TVS Motor Company's next phase of growth and innovation TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a
Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 21:27:00 CEST | Press release
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom